Providing data and support to the Trisomy 21 Society, a study was conducted to determine if health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. Whilst signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40.